Current Molecular Targets of Heterocyclic Compounds for Cancer Therapy | Agenda Bookshop Skip to content
LAST CHANCE! Order items marked '10-20 working days' TODAY to get them in time for Christmas!
LAST CHANCE! Order items marked '10-20 working days' TODAY to get them in time for Christmas!
Age Group_Uncategorized
Age Group_Uncategorized
automatic-update
B01=Ankur Vaidya
B01=Vivek Asati
Category1=Non-Fiction
Category=KJT
Category=MJCL
Category=UFL
COP=United Kingdom
Delivery_Pre-order
Language_English
PA=Not yet available
Price_€100 and above
PS=Forthcoming
softlaunch

Current Molecular Targets of Heterocyclic Compounds for Cancer Therapy

English

Current Molecular Targets of Heterocyclic Compounds for Cancer Therapy discusses recently developed treatments based on molecular targets which are genetically altered in cancer cells and are essential for tumor development and survival. Considerable research effort has been devoted to the development of targeted drugs that inhibit the action of pathogenic kinases, and clinical studies performed so far have validated the positive effects of kinase inhibitors for cancer treatment. Each chapter discusses a molecular target, such as ALK2, ATR, CK, Src-Abl, EGFR, Fyn-Blk-Lyn, IGFs, and PAK1. The book's chapters are written by experts who actively work on the targets to help readers fully understand how they can be used. This is a valuable resource for cancer researchers, oncologists, graduate students and members of the biomedical field who are interested in the potential of novel cancer therapies based on molecular targets. See more
Current price €125.99
Original price €139.99
Save 10%
Age Group_Uncategorizedautomatic-updateB01=Ankur VaidyaB01=Vivek AsatiCategory1=Non-FictionCategory=KJTCategory=MJCLCategory=UFLCOP=United KingdomDelivery_Pre-orderLanguage_EnglishPA=Not yet availablePrice_€100 and abovePS=Forthcomingsoftlaunch

Will deliver when available. Publication date 19 Apr 2024

Product Details
  • Dimensions: 191 x 234mm
  • Publication Date: 19 Apr 2024
  • Publisher: Elsevier Science & Technology
  • Publication City/Country: United Kingdom
  • Language: English
  • ISBN13: 9780323961219

About

Dr. Vivek Asati presently work as Associate Professor in the Department of Pharmaceutical Chemistry ISF College of Pharmacy Moga (Punjab) India. He previously worked as research associate in the Department of Pharmaceutical Sciences Dr H.S. Gour University Sagar (MP). He completed his PhD from the Institute of Pharmaceutical Sciences GGV Bilaspur. He has both research and industry experience gained at several organizations. His research areas include computer-aided drug designing and synthesis of various small molecule inhibitors. Dr. Asati has published research papers book chapters reviews in various peer-reviewed journals and presented own works at several national and international conferences. He Guided several M Pharm and PhD students and published patent. Dr. Ankur Vaidya did his graduation post-graduation and PhD from Dept. of Pharmaceutical Sciences Dr. H. S. Gour University Sagar (M.P.) in 2004 2008 and 2013 respectively. Dr. Vaidya has a teaching and research experience of many years and is currently working as Asst. Professor in Faculty of Pharmacy UPUMS Saifai Etawah (U.P.) India. Dr. Ankur has a key research interest in discovery of new anticancer agents with novel targets and published dozens outstanding publications in various International journals. Dr Vaidya has credited as reviewer of international journals of repute in the field of Pharmaceutical sciences. Dr. Ankur has guided several postgraduate theses and was also the recipient of AICTE-NDF (National Doctorate Fellowship) fellowship for PhD research project. Dr. Vaidya has published nternational book chapters one International book authored and 1 national book. Dr. Ankur has participated/presented in various National and International conferences.

Customer Reviews

Be the first to write a review
0%
(0)
0%
(0)
0%
(0)
0%
(0)
0%
(0)
We use cookies to ensure that we give you the best experience on our website. If you continue we'll assume that you are understand this. Learn more
Accept